A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
暂无分享，去创建一个
P. Troncoso | C. Logothetis | P. Corn | Jeri Kim | L. Pagliaro | S. Tu | A. Zurita | Xuemei Wang | A. Aparicio | E. Efstathiou | S. Wen | A. Hoang | N. Tannir | S. Subudhi | J. Araujo | A. Tsikkinis | N. Spetsieris | M. Boukovala | J. Weldon | J. Wang